• . State the primary objective(s) of the study
  
• The specific aim is to describe the difference, if any, in subjects who treat a migraine attack early (at 1 hour) with Migranal and those who treat later (at 4-hours) and relate this to the presence or absence of established cutaneous allodynia.
  

• b. State the secondary objectives(s) of the study
  
• Allodynia assessments as performed at pre-dosing, 15 minutes, 30 minutes, 1 hour, 1 ½ hours, 2 hours, 4 hours, 8 hours and 24 hours post-dosing for each attack treated per subject. Post-dosing assessments begin after the entire 4mg. dose has been adminis
  
• Pain and associated symptoms assessments as measured at pre-dose, 15 minutes, 30 minutes, 1 hour, 1 ½ hours, 2 hours, 4 hours, 8 hours and 24 hours post-dosing for each attack treated per subject. Post-dosing assessments begin after the entire 4mg. dose
  
• Subjects historical response to triptan therapy and ergot therapies
  
• Occurrence of adverse events for each attack treated per subject
  
• Use of rescue therapy for each attack treated per subject
  

Inclusion Criteria:

• Male and female subjects between the ages of 18 and 65, inclusive
• Subjects diagnosed with episodic migraine, with or without aura according to IHS criteria (Appendix B) for at least one-year prior to screening
• Subjects who experience between 3-10 migraine attacks (inclusive) per month (during the previous 6 months) with no more than 15 days of headache per month.
• Subjects who report their migraine pain quality as pulsating/ throbbing.
• Subject experiences episodic migraine associated with cutaneous allodynia, as determined by the Cutaneous Allodynia screening tool and investigator.
• Subject is using or agrees to use for the duration of participation a medically acceptable form of contraception (as determined by investigator), if female of child-bearing potential
• Subjects who are able to understand and comply with all study procedures.
• Subject provides written informed consent prior to any screening procedures being conducted

Exclusion Criteria:

• Pregnant and/or lactating women
• Subjects who, in the investigators opinion, have a history or have evidence of a medical or psychiatric condition that would expose them to an increased risk of a significant adverse event or would interfere with the assessments of efficacy and tolerability during this trial
• Subjects with an abnormal ECG that, in the investigators opinion, would expose them to increased risk of adverse events or interfere with study drug and/or analysis of efficacy/tolerability
• Subjects currently using, or expecting to use during the trial, CYP 3A4 inhibitors (such as protease inhibitors and macrolide antibiotics)
• Subjects with severely impaired hepatic or renal function, as determined by the investigator
• Subjects who have participated in an investigational drug trial in the 30 days prior to the screening visit
• Subjects who currently have or have a history of basilar or hemiplegic migraine
• Subjects who have previously shown hypersensitivity to ergot alkaloids
• Subjects who have a history of non-response to DHE-45 or Migranal®, as determined by investigator
• Subjects with uncontrolled hypertension
• Subjects who currently have or who have a history of ischemia and/or vasospastic coronary artery disease
• Subjects who, in the investigators opinion, have significant risk factors of coronary artery disease